Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,813.07 +750.66 (+1.12%) CMC Crypto 200
1,371.64 +41.03 (+3.08%)
UroGen Pharma Ltd. (0XOD.L)
| Previous close | 16.73 |
| Open | 16.53 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 16.38 - 16.53 |
| 52-week range | 7.83 - 24.01 |
| Volume | |
| Avg. volume | 457 |
| Market cap | 229.162M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.05 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWall Street Analysts See a 149.01% Upside in Urogen Pharma (URGN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 149% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Business WireUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 18, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1,142,857 ordinary shares at a purchase price of $17.499 per pre
GlobeNewswireUroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants. In connection with the proposed offering, UroGen also expects to grant the underwriters a 30-day option to purch
